Citations

Clear

4610 citation(s) found for "Lu, Brian".

Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Dewan, Pooja , Shen, Li , Jhund, Pardeep S. , Chandra, Alvin , Chiang, Lu‐May, Claggett, Brian , Desai, Akshay S. , Gong, Jianjian , Lefkowitz, Marty , Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Solomon, Scott D. , Jhund, Pardeep S , Chandra, Alvin , Claggett, Brian L , Desai, Akshay S , Lam, Carolyn S P , Lefkowitz, Martin P , Maggioni, Aldo P , Martinez, Felipe , Packer, Milton , Redfield, Margaret M , Rouleau, Jean L , Van Veldhuisen, Dirk J , Zannad, Faiez , Zile, Michael R , Solomon, Scott David , Ferreira, João Pedro , Anand, Inder S. , Lam, Carolyn S.P. , Packer, Milton , Zile, Michael R. , McMurray, John J.V.

Mayo Clinic

Circulation | June 6, 2024 | Volume: 150 | Issue: 4 | Pages: 272-282

10.1161/circulationaha.124.068774 | PMID 38841854 Get It

BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer-type dementia. To address this, we examined the effect of sacubitril/valsartan compared with valsartan on cognitive function in patients with heart failure with preserved ejection fraction in a prespecified substudy of PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). METHODS: In PARAGON-HF, serial assessment of cognitive function was conducted in a subset of patients with the Mini-Mental State Examination (MMSE; score range, 0–30, with lower scores reflecting worse cognitive function). The prespecified primary analysis of this substudy was the change from baseline in MMSE score at 96 weeks. Other post hoc analyses included cognitive decline (fall in MMSE score of ≥3 points), cognitive impairment (MMSE score <24), or the occurrence of dementia-related adverse events. RESULTS: Among 2895 patients included in the MMSE substudy with baseline MMSE score measured, 1453 patients were assigned to sacubitril/valsartan and 1442 to valsartan. Their mean age was 73 years, and the median follow-up was 32 months. The mean±SD MMSE score at randomization was 27.4±3.0 in the sacubitril/valsartan group, with 10% having an MMSE score <24; the corresponding numbers were nearly identical in the valsartan group. The mean change from baseline to 96 weeks in the sacubitril/valsartan group was −0.05 (SE, 0.07); the corresponding change in the valsartan group was −0.04 (0.07). The mean between-treatment difference at week 96 was −0.01 (95% CI, −0.20 to 0.19; P =0.95). Analyses of a ≥3-point decline in MMSE, decrease to a score <24, dementia-related adverse events, and combinations of these showed no difference between sacubitril/valsartan and valsartan. No difference was found in the subgroup of patients tested for apolipoprotein E ε4 allele genotype. CONCLUSIONS: Patients with heart failure with preserved ejection fraction in PARAGON-HF had relatively low baseline MMSE scores. Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01920711.
Diagnosis of Inflammatory Bowel Disease–Associated Peripheral Arthritis: A Systematic Review
Falloon, Katherine , Dossaji, Zahra, Mude, Pooja , Abushamma, Suha , Bhalla, Jaideep , Bhattacharya, Abhik , Cheemalavagu, Shashank , Colombel, J.F., Ha, Christina , Horst, Sara , Hou, Jason K. , Husni, M. Elaine , Kline, Theresa , Long, Millie D. , Patel, Aditi, Scherl, Ellen , Qazi, Taha , Cohen, Benjamin L, Feagan, Brian G. , Rieder, Florian , Ha, Christina , Herfarth, Hans H , Sleiman, Joseph , Qazi, Taha , Ananthakrishnan, Ashwin N. , Barnes, Edward L. , Cross, Raymond K. , Ermann, Joerg , Herfarth, Hans , Kuhn, Kristine A. , Loftus, Edward V. , Lukin, Dana J. , Rubin, David T. , Shah, Shiraz Ali , Siaton, Bernadette C. , Sleiman, Joseph , Weisman, Michael H. , Cohen, Benjamin L

Mayo Clinic

Inflammatory Bowel Diseases | June 5, 2024 | Volume: 31 | Issue: 3 | Pages: 812-842

10.1093/ibd/izae114 | PMID 38836521 Get It

Abstract Background Inflammatory bowel disease (IBD)–associated peripheral spondyloarthritis (pSpA) decreases quality of life and remains poorly understood. Given the prevalence of this condition and its negative impact, it is surprising that evidence-based disease definitions and diagnostic strategies are lacking. This systematic review summarizes available data to facilitate development and validation of diagnostics, patient-reported outcomes, and imaging indices specific to this condition. Methods A literature search was conducted. Consensus or classification criteria, case series, cross-sectional studies, cohort studies, and randomized controlled trials related to diagnosis were included. Results A total of 44 studies reporting data on approximately 1500 patients with pSpA were eligible for analysis. Data quality across studies was only graded as fair to good. Due to large heterogeneity, meta-analysis was not possible. The majority of studies incorporated patient-reported outcomes and a physical examination. A total of 13 studies proposed or validated screening tools, consensus, classification, or consensus criteria. A total of 28 studies assessed the role of laboratory tests, none of which were considered sufficiently accurate for use in diagnosis. A total of 17 studies assessed the role of imaging, with the available literature insufficient to fully endorse any imaging modality as a robust diagnostic tool. Conclusions This review highlights existing inconsistency and lack of a clear diagnostic approach for IBD-associated pSpA. Given the absence of an evidence-based approach, a combination of existing criteria and physician assessment should be utilized. To address this issue comprehensively, our future efforts will be directed toward pursuit of a multidisciplinary approach aimed at standardizing evaluation and diagnosis of IBD-associated pSpA.
Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer.
Hocum, Brian , Grossman, Jamie M., Appukkuttan, Sreevalsa , Babajanyan, Svetlana , Lee, Woojung , Cho, Sang Kyu , Bekaii‐Saab, Tanios , Grossman, Jamie, Yang, Min Jae , Barzi, Afsaneh

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3525-3525

10.1200/jco.2024.42.16_suppl.3525 Get It

3525 Background: Recent clinical trials support regorafenib dose optimization (ReDO), a combination therapy with trifluridine/tipiracil and bevacizumab (TAS-BEV), and fruquintinib (FRUQ) for the treatment of refractory metastatic colorectal cancer (mCRC). This study evaluated relative cost-effectiveness of ReDO, TAS-BEV, and FRUQ for mCRC from a payer perspective in the United States. Methods: A Markov model was constructed to estimate total costs and quality-adjusted life years (QALY) for each treatment. In the base case, clinical parameters were obtained from the ReDOS study for ReDO, the SUNLIGHT study for TAS-BEV, and the FRESCO study for FRUQ. Economic parameters were obtained from IBM Micromedex RED BOOK for treatment costs and from the Centers for Medicare & Medicaid Services and the Agency for Healthcare Research and Quality for health care resource use. Incremental cost-effectiveness ratio (ICER) was used to evaluate relative cost-effectiveness of treatments. Model robustness was checked with deterministic (DSA) and probabilistic sensitivity analysis (PSA). A subgroup analysis was performed in patients with and without previous use of anti-VEGF therapy, but using the FRESCO-2 study for FRUQ because OS and PFS for this subgroup was unavailable in the FRESCO study. Results: In the base case, ReDO provided a higher QALY at a lower cost than TAS-BEV and FRUQ. During the first two months following treatment initiation, TAS-BEV had a higher total cost ($67,862) than ReDO ($44,695) and FRUQ ($48,688), partly due to the cost of managing neutropenia and using concomitant granulocyte colony stimulating factors (GCSF). The base case results were robust in DSA and PSA. Most influential parameters determining relative cost-effectiveness were related to treatment cost and effectiveness. In patients with previous anti-VEGF therapy, ReDO provided a higher QALY at a lower cost (0.571 QALY; $86,694) than TAS-BEV (0.490 QALY; $148,784) and FRUQ (0.411 QALY; $101,236). In patients without previous anti-VEGF therapy, TAS-BEV had a higher QALY (0.755 vs 0.571) and a higher cost ($232,701 vs $86,694) than ReDO, resulting in an ICER of $790,988 per QALY. Conclusions: ReDO was cost-effective compared with TAS-BEV and FRUQ, regardless of previous use of anti-VEGF therapy. In the base case, ReDO had a lower treatment cost than TAS-BEV and FRUQ, especially during the first month of dose optimization. TAS-BEV had the highest total cost, partly due to the cost of managing neutropenia and GCSF use. [Table: see text]
International Hackathon as a Tool to Augment Education, Collaboration, and Innovation in Global Neurosurgery
Razak, Shahaan S. , Tunsiricharoengul, Sasha, Nair-Kanneganti, Aparna, Perez, Nicole A , Duvall, Julia B. , Rigney, Grant , Cerda, Ivo H. , Morcos, Mary , Keay, Emma, Hernández, Alejandra Silva, Lawton, Michael T. , Nahed, Brian V. , Quiñones‐Hinojosa, Alfredo , Quinones-Hinojosa, Alfredo , West, Timothy R. , Tunsiricharoengul, Sasha, Mazurek, Mercy H. , Gal, Zsombor Tamas

Mayo Clinic

Neurosurgery | June 4, 2024 | Volume: 95 | Issue: 2 | Pages: 480-486

10.1227/neu.0000000000002991 | PMID 39008546 Get It

BACKGROUND AND OBJECTIVES: Health care providers' exposure to global surgical disparities is limited in current nursing and/or medical school curricula. For instance, global health is often associated with infectious diseases or maternal health without acknowledging the growing need for surgical care in low- and middle-income countries (LMICs). We propose an international virtual hackathon based on neurosurgical patient cases in under-resourced settings as an educational tool to bring awareness to global surgical disparities and develop relationships among trainees in different countries. METHODS: Participants were recruited through email listservs, a social media campaign, and prize offerings. A 3-day virtual hackathon event was administered, which included workshops, mentorship, keynote panels, and pitch presentations to judges. Participants were presented with real patient cases and directed to solve a barrier to their care. Surveys assessed participants' backgrounds and event experience. The hackathon was executed through Zoom at Harvard Innovation Lab in Boston, MA, on March 25 to 27, 2022. Participants included medical students, with additional participants from business, engineering, or current health care workers. RESULTS: Three hundred seven applications were submitted for 100 spots. Participants included medical students, physicians, nurses, engineers, entrepreneurs, and undergraduates representing 25 countries and 82 cities. Fifty-one participants previously met a neurosurgeon, while 39 previously met a global health expert, with no difference between LMIC and high-income countries' respondents. Teams spent an average of 2.75 hours working with mentors, and 88% of postevent respondents said the event was “very” or “extremely conducive” to networking. Projects fell into 4 categories: access, language barriers, education and training, and resources. The winning team, which was interdisciplinary and international, developed an application that analyzes patient anatomy while performing physical therapy to facilitate remote care and clinical decision-making. CONCLUSION: An international virtual hackathon can be an educational tool to increase innovative ideas to address surgical disparities in LMICs and establish early collaborative relationships with medical trainees from different countries.
The relationship of rate and pause features to the communicative participation of people living with ALS
Connaghan, Kathryn P. , Green, Jordan R. , Eshghi, Marziye , Haenssler, Abigail E. , Scheier, Zoe A. , Clark, Alison , Iyer, Amrita , Richburg, Brian , Rowe, Hannah P. , Okada, June , Johnson, Stephen A , Onnela, Jukka-Pekka , Burke, Katherine M , Berry, James D , Johnson, Stephen A. , Burke, Katherine M. , Berry, James D.

Mayo Clinic

Muscle & Nerve | June 4, 2024 | Volume: 70 | Issue: 2 | Pages: 217-225

10.1002/mus.28170 | PMID 38837773 Get It

AbstractIntroduction/AimsMany people living with amyotrophic lateral sclerosis (PALS) report restrictions in their day‐to‐day communication (communicative participation). However, little is known about which speech features contribute to these restrictions. This study evaluated the effects of common speech symptoms in PALS (reduced overall speaking rate, slowed articulation rate, and increased pausing) on communicative participation restrictions.MethodsParticipants completed surveys (the Communicative Participation Item Bank‐short form; the self‐entry version of the ALS Functional Rating Scale‐Revised) and recorded themselves reading the Bamboo Passage aloud using a smartphone app. Rate and pause measures were extracted from the recordings. The association of various demographic, clinical, self‐reported, and acoustic speech features with communicative participation was evaluated with bivariate correlations. The contribution of salient rate and pause measures to communicative participation was assessed using multiple linear regression.ResultsFifty seven people living with ALS participated in the study (mean age = 61.1 years). Acoustic and self‐report measures of speech and bulbar function were moderately to highly associated with communicative participation (Spearman rho coefficients ranged from rs = 0.48 to rs = 0.77). A regression model including participant age, sex, articulation rate, and percent pause time accounted for 57% of the variance of communicative participation ratings.DiscussionEven though PALS with slowed articulation rate and increased pausing may convey their message clearly, these speech features predict communicative participation restrictions. The identification of quantitative speech features, such as articulation rate and percent pause time, is critical to facilitating early and targeted intervention and for monitoring bulbar decline in ALS.
Management of failed flow diversion for intracranial aneurysm beyond the first 6 months of follow-up: an international Delphi consensus
Chintapalli, Renuka , Nguyen, Sarah, Dammann, Philipp , Raygor, Kunal P. , Ogilvy, Christopher S. , Linfante, Italo , Almefty, Rami O. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Starke, Robert M. , Gross, Bradley A. , Kan, Peter, Coulthard, Alan , Dabus, Guilherme , Raper, Daniel , Kilburg, Craig , Abla, Adib A. , Abla, Adib , Ogilvy, Christopher S , Burkhardt, Jan‐Karl , Nguyen, Sarah E. , Taussky, Philipp , Grandhi, Ramesh , Tonetti, Daniel A. , Andersson, Tommy , White, Phil , Chapot, René , Fox, W Christopher , Tawk, Rabih G. , Lanzino, Giuseppe , Hanel, Ricardó A. , Jadhav, Ashutosh P. , Hassan, Ameer E , Mascitelli, Justin R , Fargen, Kyle M , Levitt, Michael R. , Jabbour, Pascal , Gross, Bradley , Killer-Oberpfalzer, Monika , Rautio, Riitta , Dmytriw, Adam A. , Dabus, Guilherme C. , Deuschl, Cornelius , Budohoski, Karol P.

Mayo Clinic

Journal of Neurosurgery | June 1, 2024 | Volume: 141 | Issue: 5 | Pages: 1225-1234

10.3171/2024.3.jns2499 | PMID 38820616 Get It

OBJECTIVE The placement of flow-diverting devices has become a common method of treating unruptured intracranial aneurysms of the internal carotid artery. The progressive improvement of aneurysm occlusion after treatment—with low complication and rupture rates—has led to a dilemma regarding the management of aneurysms in which occlusion has not occurred within 6–24 months. The authors aimed to identify clinical consensus regarding management of intracranial aneurysms displaying persistent filling 6–24 months after flow diversion and to ascertain questions that may drive future investigation. METHODS An international panel of 67 experts was invited to participate in a multistep Delphi consensus process on the treatment of intracranial aneurysms after failed flow diversion. RESULTS Of the 67 experts invited, 23 (34%) participated. Qualitative analysis of an initial survey with open-ended questions resulted in 51 statements regarding management of aneurysms showing persistent filling after flow diversion. The statements were grouped into 8 categories, and in the second round, respondents rated the degree of their agreement with each statement on a 5-point Likert scale. Flow diverters with surface modifiers did not influence administration of dual-antiplatelet therapy according to 83%. Consensus was also reached regarding the definition of treatment failure at specific time points, including at 6 months if there is aneurysm growth or persistent rapid flow through the entirety of the aneurysm (96%), at 12 months if there is aneurysm growth or symptom onset (78%), and at 24 months if there is persistent filling regardless of size and filling characteristics (74%). Although experts agreed that the degree of intimal hyperplasia or in-device stenosis could not be ascertained by noninvasive imaging alone (83%), only 65% chose digital subtraction angiography as the preferred modality. At 6 and 12 months, retreatment is preferred if there is persistent filling with aneurysm growth (96%, 96%), device malposition (48%, 87%), or a history of subarachnoid hemorrhage (65%, 70%), respectively, and at 24 months if there is persistent filling without reduction in aneurysm size (74%). Experts favored treatment with an additional flow diverter (87%) over aneurysm clipping, applying the same principles for follow-up (83%) and treatment failure (91%) as for the first flow diverter. CONCLUSIONS The authors present the consensus practices of experts in the management of intracranial aneurysms without occlusion 6–24 months after treatment with a flow-diverting device.
BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression
Rivero, Seleste L, Shen, Keyi , Li, Zixuan , Niu, Tianhua , Rowan, Brian G., Jazwinski, S. Michal, Steele, Chad , Wang, Alun R. , Zhang, Qiuyang , Zhang, Qiuyang , Liu, Sen , Zhang, Bing , Abdel‐Mageed, Asim B. , Sartor, Oliver

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 1, 2024 | Volume: 116 | Issue: 10 | Pages: 1598-1611

10.1093/jnci/djae120 | PMID 38833676 Get It

Abstract Background The role of Th17 cells in prostate cancer is not fully understood. The transcription factor BATF controls the differentiation of Th17 cells. Mice deficient in Batf do not produce Th17 cells. Methods In this study, we aimed to characterize the role of Batf-dependent Th17 cells in prostate cancer by crossbreeding Batf knockout mice with mice conditionally mutant for Pten. Results We found that Batf knockout mice had changes in the morphology of prostate epithelial cells compared with normal mice, and Batf knockout mice deficient in Pten (called Batf-) had smaller prostate size and developed fewer invasive prostate adenocarcinomas than Pten-deficient mice with Batf expression (called Batf+). The prostate tumors in Batf- mice showed reduced proliferation, increased apoptosis, decreased angiogenesis and inflammatory cell infiltration, and activation of nuclear factor–κB signaling. Moreover, Batf- mice showed significantly reduced interleukin 23 (IL-23)-IL-23R signaling. In the prostate stroma of Batf- mice, IL-23R–positive cells were decreased considerably compared with Batf+ mice. Splenocytes and prostate tissues from Batf- mice cultured under Th17 differentiation conditions expressed reduced IL-23/IL-23R than cultured cells from Batf+ mice. Anti–IL-23p19 antibody treatment of Pten-deficient mice reduced prostate tumors and angiogenesis compared with control immunoglobulin G–treated mice. In human prostate tumors, BATF messenger RNA level was positively correlated with IL-23A and IL-23R but not RORC. Conclusion Our novel findings underscore the crucial role of IL-23-IL-23R signaling in mediating the function of Batf-dependent Th17 cells, thereby promoting prostate cancer initiation and progression. This finding highlights the BATF–IL-23R axis as a promising target for the development of innovative strategies for prostate cancer prevention and treatment.
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Smith, Mitchell R. , Jegede, Opeyemi A. , Parekh, Samir , Yang, David T. , Hsi, Eric D. , Witzig, Thomas E. , Davé, Sandeep S. , Scott, David W. , Hanson, Curtis A. , Shields, Lale Kostakoglu, Abdel‐Samad, Nizar, Baghdadi, Tareq Al, Blum, Kristie A. , Romer, Mark D., Inwards, David J. , Lerner, Rachel E. , Little, Richard F. , Friedberg, Jonathan W. , Leonard, John P. , Witzig, T.E. , Yang, David , Hsi, Eric D , Scott, David W , Hanson, Curtis, Casulo, Carla , Wagner, Lynne , Little, Richard F , Kahl, Brad S , Jagede, Opeyemi A. , Parekh, Samir , Baghdadi, Tareq Al , Martin, Peter, Till, Brian G. , Casulo, Carla , Bartlett, Nancy L. , Caimi, Paolo F. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Blood | May 31, 2024 | Volume: 144 | Issue: 10 | Pages: 1083-1092

10.1182/blood.2024023962 | PMID 38820500 Get It

Abstract Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged ≥60 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-naïve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the &gt;5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies
Mahmoud, Ahmed , Moustafa, Amr A. , Day, Carter, Ahmed, Mohamed E. , Zeina, Wael, Marzouk, Usama M., Haloi, Rimki , Mahon, Mindie, Muniz, Miguel, Orme, Jacob J. , Kendi, A. Tuba , Stish, Bradley J. , Kwon, Eugene D., Andrews, Jack R. , Mahmoud, Ahmed M , Moustafa, Amr , Basourakos, Spyridon, Muniz, Miguel , Childs, Daniel S , Orme, Jacob J , Riaz, Irbaz Bin , Kendi, A Tuba , Davis, Brian J. , Ahmed, Mohamed , Moustafa, Amr, Basourakos, Spyridon P. , Childs, Daniel S.

Mayo Clinic

Cancers | May 30, 2024 | Volume: 16 | Issue: 11 | Pages: 2080

10.3390/cancers16112080 | PMID 38893199 Get It

Prostate cancer lung metastasis represents a clinical conundrum due to its implications for advanced disease progression and the complexities it introduces in treatment planning. As the disease progresses to distant sites such as the lung, the clinical management becomes increasingly intricate, requiring tailored therapeutic strategies to address the unique characteristics of metastatic lesions. This review seeks to synthesize the current state of knowledge surrounding prostate cancer metastasis to the lung, shedding light on the diverse array of clinical presentations encountered, ranging from subtle radiological findings to overt symptomatic manifestations. By examining the diagnostic modalities utilized in identifying this metastasis, including advanced imaging techniques and histopathological analyses, this review aims to provide insights into the diagnostic landscape and the challenges associated with accurately characterizing lung metastatic lesions in prostate cancer patients. Moreover, this review delves into the nuances of therapeutic interventions employed in managing prostate cancer lung metastasis, encompassing systemic treatments such as hormonal therapies and chemotherapy, as well as metastasis-directed therapies including surgery and radiotherapy.
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.
Hennessy, Maeve, Gatsonis, Constantine, Jacene, Heather A. , Connolly, Roisín M. , Burnette, Brian L., Stringer-Reasor, Erica , Taurone, Alexander, O’Sullivan, Ciara C. , Le‐Petross, Huong T. , Sepulveda, Karla A., Romanoff, Justin , Lawhn-Heath, Courtney A. , Stearns, Vered , Fowler, Amy M. , Tang, Shou-Ching , DeMichele, Angela , Mankoff, David A. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS614-TPS614

10.1200/jco.2024.42.16_suppl.tps614 Get It

TPS614 Background: Strategies to optimize treatment decision-making in early stage HER2-positive breast cancer are a priority. Recent studies suggest that early metabolic changes on FDG-PET/CT predict response to HER2-directed therapy. The TBCRC026 trial showed that participants not obtaining a 40% reduction in SULmax by cycle 1 day 15 (C1D15) following neoadjuvant trastuzumab/pertuzumab (HP) were unlikely to obtain pCR [negative predictive value (NPV) 91%]. This trial aims to validate FDG-PET/CT as a neoadjuvant interim (niFDG-PET/CT) imaging integral biomarker in patients treated with standard HER2-directed regimens (NCT05710328). Methods: Trial design: EA1211/DIRECT is a multicenter, single-arm, primary imaging phase 2 study enrolling patients with stage II/III HER2-positive breast cancer. Patients undergo standard skull base-thigh FDG-PET/CT at baseline and C1D15 and receive standard of care pertuzumab-based neoadjuvant therapy followed by surgery. Eligibility: Age ≥18 years, ECOG performance status 0-2, stage IIa-IIIc, untreated HER2-positive breast cancer with known hormone receptor status, suitable to undergo FDG-PET/CT imaging and neoadjuvant therapy. Statistical methods: ΔSULmaxD15 will be computed as: (D15 SULmax – baseline SULmax)/baseline SULmax. The primary objective is to estimate the NPV of niFDG-PET/CT for pCR using ΔSULmaxD15 of the primary breast cancer at a threshold of 40%. NPV is defined as the probability that pCR will not be achieved by participants with ΔSULmaxD15 <40%. Secondary endpoints include evaluating sensitivity, specificity, and positive predictive value of ΔSULmaxD15 of the primary breast cancer at a threshold of 40% and ability of the niFDG-PET/CT biomarker to predict 3-year event free survival (EFS). Sample size: We expect that 50% of patients will not reach the ΔSULmax threshold of 40% and a pCR rate of 40-60%. The proposed sample size is 210 participants, adjusted to 235 to account for missing data in 10% of cases. Computation of exact, two-sided 95% confidence intervals (CI) for NPV determined the lower limit of the CI is at least 80% when the true NPV is at least 88%. The lower limit is 84% when the true NPV has the value of 91%, which was estimated in the TBCRC026 study. Current status: EA1211/DIRECT was activated in May 2023 across the NCI National Clinical Trials Network (NCTN) and is anticipated to complete in March 2025. Those interested in the clinical trial can email ea1211team@ecog-acrin.org. The EA1211/DIRECT trial is the first step in implementing a Response-Guided Treatment Strategy by validating the ΔSULmax threshold of 40% as the optimum cut point across standard of care HER2-directed neoadjuvant regimens. If EA1211/DIRECT meets its objectives, the results will be used to design clinical utility studies, thus hoping to change practice. Clinical trial information: NCT05710328 .